Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Leukemia. 2017 Nov 3;32(4):920–930. doi: 10.1038/leu.2017.321

Figure 2. Changes in chemokine levels and inhibition of chemotaxis during acalabrutinib therapy.

Figure 2

(A) Levels of CCL3 in plasma at baseline (day 0) and 8 and 28 days of therapy. (B) Levels of CCL4 in plasma at baseline and 8 and 28 days of therapy. Levels of chemokines were measured using ELISA assay as described in the Methods. (C) Changes in chemotaxis after acalabrutinib therapy. Lymphocytes were isolated from 6 patients before (day 0) and after days 8 and 28 of acalabrutinib therapy. Cells were incubated without (control [CNT]) or with chemokine (SDF-1) for 3 hours, and migration of cells was accessed as described in the Methods.